The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study results presented at ESMO Congress.Final results of the randomized ...

Nivolumab plus ipilimumab was also associated with a significant improvement in the median duration of response (30.4 months [95% CI, 21.2-not evaluable] vs 12.9 months ...

Median PFS with nivolumab + ipilimumab vs nivolumab monotherapy was not reached vs 39.3 months, respectively (HR, 0.62), and the overall response rates were 71% and 58%, respectively.

First-line nivolumab plus ipilimumab significantly extended OS compared with platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma, according to results of an ...

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

The median overall survival (OS) was 52.7 months with nivolumab-ipilimumab and 37.8 months with sunitinib (HR, 0.72; 95% CI 0.62-0.83). The estimated 90-month OS rates were 35.1% and 24.9% ...

In the phase I or II CheckMate 032 trial, clinical activity with nivolumab and nivolumab plus ipilimumab was observed for relapsed SCLC. 11-13 However, nivolumab did not improve survival over ...

Among 26 evaluable patients with clear cell ovarian or endometrial cancer, the objective response rate with the regimen was 54%, with 12 patients achieving a partial response, and three achieving a ...

The sBLA was based on data from the open-label, multicenter, randomized phase 3 CheckMate -9LA trial that compared the efficacy of nivolumab plus ipilimumab in combination with chemotherapy to ...

Yao T, Kang YK, Kim TU, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in few responses among patients who did not achieve a response with nivolumab alone, according to ...